Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

Posted on by

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 26 Mar 2022)

 

Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
From January to May 2021 the alpha variant (B.1.1.7) of SARS-CoV-2 was the most commonly detected variant in the UK. Following this, the Delta variant (B.1.617.2) then became the predominant variant. The UK CO…
Authors: Karan Pattni, Daniel Hungerford, Sarah Adams, Iain Buchan, Christopher P. Cheyne, Marta García-Fiñana, Ian Hall, David M. Hughes, Christopher E. Overton, Xingna Zhang and Kieran J. Sharkey
Citation: BMC Infectious Diseases 2022 22:270
Content type: Research article Published on: 20 March 2022